Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Details Textual)

v2.4.0.8
Commitments and Contingencies (Details Textual) (USD $)
0 Months Ended 12 Months Ended 12 Months Ended 12 Months Ended 3 Months Ended 12 Months Ended 101 Months Ended 12 Months Ended
Feb. 05, 2012
Oct. 01, 2011
Oct. 01, 2010
Mar. 05, 2009
Nov. 10, 2008
Oct. 01, 2008
Sep. 29, 2008
Sep. 19, 2008
Jun. 29, 2007
Dec. 31, 2013
Dec. 31, 2012
Jun. 30, 2011
Sep. 30, 2009
Aug. 31, 2009
Jul. 06, 2006
Mar. 22, 2006
Dec. 31, 2013
Dr. Von Hoff [Member]
Dec. 31, 2013
Subsequent Event [Member]
Dec. 31, 2013
Subsequent Event [Member]
Dr. Von Hoff [Member]
Dec. 31, 2013
Subsequent Event [Member]
Consulting Agreement [Member]
Dec. 31, 2013
Subsequent Event [Member]
Consulting Agreement [Member]
Dr. Von Hoff [Member]
Dec. 31, 2013
Subsequent Event [Member]
Consulting Agreement [Member]
Dr. Von Hoff [Member]
Dec. 31, 2013
Agreement With Theradex Systems [Member]
Dec. 31, 2012
Agreement With Theradex Systems [Member]
Dec. 31, 2013
Agreement With Theradex Systems [Member]
Sep. 21, 2012
Agreement With Theradex Systems [Member]
Dec. 31, 2013
Agreement With Ascentage Pharma Group [Member]
Dec. 31, 2013
Other Unrelated Vendor [Member]
Commitments And Contingencies [Line Items]                                                        
Cooperative Research and Development Project Commitments, Amount                         $ 200,000 $ 100,000   $ 200,000                        
Cooperative Research Commitments Due, Current                             200,000                          
Payments To Fund Cooperative Research and Development 25,000 25,000 50,000 50,000   50,000 50,000   200,000                                      
National Institute Of Health Patent License Agreement, Terms               The PLA provided for an initial payment of $25,000 to the NIH within 60 days of September 19, 2008, and for a minimum annual royalty of $30,000 on January 1 of each calendar year following the year in which the CRADA is terminated.                                        
Patent License Agreement, Minimum Annual Royalty, Amount                                   30,000                    
Payments To National Institute Of Health Patent License Agreement Initial Payment         25,000                                              
Research and Development Contract, Estimated Cost, Various Clinical Studies                                                     29,025 104,100
Research and Development Contract, Payments For Various Clinical Studies                                                     17,415 75,325
Principal Cash Obligations and Commitments, Current                   213,000                                    
Annual Fee Payable, Clinical Trial                                                   2,000,000    
Fees For Services Total                   14,964 163,661                       14,964 163,661 194,551      
Clinical Cost Charged To Operations Total                                             278,721          
Charges To Operations                   7,275 24,500                                  
Consulting Fees                                         $ 4,000              
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross                                 100,000     4,000,000   100,000            
Stock Options Vested                   150,000                 25,000     25,000            
Stock Option Vested In Next Twelve Months                                           25,000            
Stock Option Vested In Year Two                                           25,000            
Stock Option Vested In Year Three                                           25,000            
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price                   $ 0.843 $ 0.876 $ 0.98         $ 0.13     $ 0.50 $ 0.13 $ 0.13